

Product datasheet for **MR209019L3V**

Fbxw5 (NM_013908) Mouse Tagged ORF Clone Lentiviral Particle

Product data:

Product Type:	Lentiviral Particles
Symbol:	Fbxw5
Synonyms:	AI159739; Fbw5
Mammalian Cell Selection:	Puromycin
Vector:	pLenti-C-Myc-DDK-P2A-Puro (PS100092)
Tag:	Myc-DDK
ACCN:	NM_013908
ORF Size:	1719 bp

ORF Nucleotide Sequence: The ORF insert of this clone is exactly the same as(MR209019).

OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. [More info](#)

OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.

RefSeq:	NM_013908.2
RefSeq Size:	2359 bp
RefSeq ORF:	1722 bp
Locus ID:	30839
UniProt ID:	Q9QXW2
Cytogenetics:	2 A3



Gene Summary:

Substrate recognition component of both SCF (SKP1-CUL1-F-box protein) and DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complexes. Substrate-specific adapter of the DCX(FBXW5) E3 ubiquitin-protein ligase complex which mediates the polyubiquitination and subsequent degradation of TSC2. May also act as a negative regulator of MAP3K7/TAK1 signaling in the interleukin-1B (IL1B) signaling pathway. Substrate recognition component of the SCF(FBXW5) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of SASS6 during S phase, leading to prevent centriole reduplication (By similarity). The SCF(FBXW5) complex also mediates ubiquitination and degradation of actin-regulator EPS8 during G2 phase, leading to the transient degradation of EPS8 and subsequent cell shape changes required to allow mitotic progression. [UniProtKB/Swiss-Prot Function]